Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis

Xanthine oxidoreductase (XOR) is generally known as the final enzyme in purine metabolism and as a source of reactive oxygen species (ROS). In addition, this enzyme has been suggested to mediate nitric oxide (NO) formation via reduction of inorganic nitrate and nitrite. This NO synthase (NOS)-indepe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Free radical biology & medicine 2016-10, Vol.99, p.472-484
Hauptverfasser: Peleli, Maria, Zollbrecht, Christa, Montenegro, Marcelo F, Hezel, Michael, Zhong, Jianghong, Persson, Erik G, Holmdahl, Rikard, Weitzberg, Eddie, Lundberg, Jon O, Carlström, Mattias
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 484
container_issue
container_start_page 472
container_title Free radical biology & medicine
container_volume 99
creator Peleli, Maria
Zollbrecht, Christa
Montenegro, Marcelo F
Hezel, Michael
Zhong, Jianghong
Persson, Erik G
Holmdahl, Rikard
Weitzberg, Eddie
Lundberg, Jon O
Carlström, Mattias
description Xanthine oxidoreductase (XOR) is generally known as the final enzyme in purine metabolism and as a source of reactive oxygen species (ROS). In addition, this enzyme has been suggested to mediate nitric oxide (NO) formation via reduction of inorganic nitrate and nitrite. This NO synthase (NOS)-independent pathway for NO generation is of particular importance during certain conditions when NO bioavailability is diminished due to reduced activity of endothelial NOS (eNOS) or increased oxidative stress, including aging and cardiovascular disease. The exact interplay between NOS- and XOR-derived NO generation is not fully elucidated yet. The aim of the present study was to investigate if eNOS deficiency is associated with changes in XOR expression and activity and the possible impact on nitrite, NO and ROS homeostasis. Plasma levels of nitrate and nitrite were similar between eNOS deficient (eNOS ) and wildtype (wt) mice. XOR activity was upregulated in eNOS compared with wt, but not in nNOS , iNOS or wt mice treated with the non-selective NOS inhibitor L-NAME. Following an acute dose of nitrate, plasma nitrite increased more in eNOS compared with wt, and this augmented response was abolished by the selective XOR inhibitor febuxostat. Livers from eNOS displayed higher nitrite reducing capacity compared with wt, and this effect was attenuated by febuxostat. Dietary supplementation with nitrate increased XOR expression and activity, but concomitantly reduced superoxide generation. The latter effect was also seen in vitro after nitrite administration. Treatment with febuxostat elevated blood pressure in eNOS , but not in wt mice. A high dose of dietary nitrate reduced blood pressure in naïve eNOS mice, and again this effect was abolished by febuxostat. In conclusion, eNOS deficiency is associated with an upregulation of XOR facilitating the nitrate-nitrite-NO pathway and decreasing the generation of ROS. This interplay between XOR and eNOS is proposed to play a significant role in NO homeostasis and blood pressure regulation.
doi_str_mv 10.1016/j.freeradbiomed.2016.09.004
format Article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_502536</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1835371262</sourcerecordid><originalsourceid>FETCH-LOGICAL-p286t-8e03e11b7eebd6f43c3a6abc16da51a2270d0cdbcf2cadc58caa16d4494169b33</originalsourceid><addsrcrecordid>eNp1kc1r3DAQxUVoyMe2_0IQ9NJD7erDlu3eQrpJCmEN2bb0JsbSOKvsru1YcsL-91HItuSS03u8-fEYZgj5zFnKGVff7tN2RBzBNq7fok1FDFNWpYxlB-SEl4VMsrxSH974Y3Lq_T2LRC7LI3IsCsUqIfITsp53K-gMWvq3vqVggnt0YUddR3FRLxOLrTMOu0C3zuB3Om9bNMHTvqNhhbRzYYSAyYu6qIuaDhBWT7Cj0Fl6Wy_pKu7Y-wDe-Y_ksIWNx097nZHfl_NfF9fJTX318-L8JhlEqUJSIpPIeVMgNla1mTQSFDSGKws5ByEKZpmxjWmFAWvy0gDEWZZVGVdVI-WMJK-9_gmHqdHD6LYw7nQPTu-jdXSocyZyqSL_9V3-h_tzrvvxTk-TlpwVRRnxL6_4MPYPE_qgt84b3Gygw37ympcylwUXSkT0bI9OTXzV_-Z_95fPC0GN3Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835371262</pqid></control><display><type>article</type><title>Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Peleli, Maria ; Zollbrecht, Christa ; Montenegro, Marcelo F ; Hezel, Michael ; Zhong, Jianghong ; Persson, Erik G ; Holmdahl, Rikard ; Weitzberg, Eddie ; Lundberg, Jon O ; Carlström, Mattias</creator><creatorcontrib>Peleli, Maria ; Zollbrecht, Christa ; Montenegro, Marcelo F ; Hezel, Michael ; Zhong, Jianghong ; Persson, Erik G ; Holmdahl, Rikard ; Weitzberg, Eddie ; Lundberg, Jon O ; Carlström, Mattias</creatorcontrib><description>Xanthine oxidoreductase (XOR) is generally known as the final enzyme in purine metabolism and as a source of reactive oxygen species (ROS). In addition, this enzyme has been suggested to mediate nitric oxide (NO) formation via reduction of inorganic nitrate and nitrite. This NO synthase (NOS)-independent pathway for NO generation is of particular importance during certain conditions when NO bioavailability is diminished due to reduced activity of endothelial NOS (eNOS) or increased oxidative stress, including aging and cardiovascular disease. The exact interplay between NOS- and XOR-derived NO generation is not fully elucidated yet. The aim of the present study was to investigate if eNOS deficiency is associated with changes in XOR expression and activity and the possible impact on nitrite, NO and ROS homeostasis. Plasma levels of nitrate and nitrite were similar between eNOS deficient (eNOS ) and wildtype (wt) mice. XOR activity was upregulated in eNOS compared with wt, but not in nNOS , iNOS or wt mice treated with the non-selective NOS inhibitor L-NAME. Following an acute dose of nitrate, plasma nitrite increased more in eNOS compared with wt, and this augmented response was abolished by the selective XOR inhibitor febuxostat. Livers from eNOS displayed higher nitrite reducing capacity compared with wt, and this effect was attenuated by febuxostat. Dietary supplementation with nitrate increased XOR expression and activity, but concomitantly reduced superoxide generation. The latter effect was also seen in vitro after nitrite administration. Treatment with febuxostat elevated blood pressure in eNOS , but not in wt mice. A high dose of dietary nitrate reduced blood pressure in naïve eNOS mice, and again this effect was abolished by febuxostat. In conclusion, eNOS deficiency is associated with an upregulation of XOR facilitating the nitrate-nitrite-NO pathway and decreasing the generation of ROS. This interplay between XOR and eNOS is proposed to play a significant role in NO homeostasis and blood pressure regulation.</description><identifier>ISSN: 1873-4596</identifier><identifier>ISSN: 0891-5849</identifier><identifier>EISSN: 1873-4596</identifier><identifier>DOI: 10.1016/j.freeradbiomed.2016.09.004</identifier><identifier>PMID: 27609225</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Blood Pressure - drug effects ; Endothelial nitric oxide synthase ; Enzyme Inhibitors - pharmacology ; Febuxostat ; Febuxostat - pharmacology ; Gene Expression Regulation ; Hypertension ; Male ; Mice ; Mice, Knockout ; NG-Nitroarginine Methyl Ester - pharmacology ; Nitrate ; Nitrates - blood ; Nitrates - pharmacology ; Nitric oxide ; Nitric Oxide - blood ; Nitric Oxide Synthase Type I - antagonists &amp; inhibitors ; Nitric Oxide Synthase Type I - deficiency ; Nitric Oxide Synthase Type I - genetics ; Nitric Oxide Synthase Type II - antagonists &amp; inhibitors ; Nitric Oxide Synthase Type II - deficiency ; Nitric Oxide Synthase Type II - genetics ; Nitric Oxide Synthase Type III - antagonists &amp; inhibitors ; Nitric Oxide Synthase Type III - deficiency ; Nitric Oxide Synthase Type III - genetics ; Nitrite ; Nitrites - blood ; Nitrites - pharmacology ; Oxidation-Reduction ; Oxidative stress ; Reactive oxygen species ; Signal Transduction ; Superoxide ; Superoxides - metabolism ; Uric acid ; Xanthine Dehydrogenase - antagonists &amp; inhibitors ; Xanthine Dehydrogenase - genetics ; Xanthine Dehydrogenase - metabolism ; Xanthine oxidase ; Xanthine oxidoreductase</subject><ispartof>Free radical biology &amp; medicine, 2016-10, Vol.99, p.472-484</ispartof><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27609225$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-310778$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:134585056$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Peleli, Maria</creatorcontrib><creatorcontrib>Zollbrecht, Christa</creatorcontrib><creatorcontrib>Montenegro, Marcelo F</creatorcontrib><creatorcontrib>Hezel, Michael</creatorcontrib><creatorcontrib>Zhong, Jianghong</creatorcontrib><creatorcontrib>Persson, Erik G</creatorcontrib><creatorcontrib>Holmdahl, Rikard</creatorcontrib><creatorcontrib>Weitzberg, Eddie</creatorcontrib><creatorcontrib>Lundberg, Jon O</creatorcontrib><creatorcontrib>Carlström, Mattias</creatorcontrib><title>Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis</title><title>Free radical biology &amp; medicine</title><addtitle>Free Radic Biol Med</addtitle><description>Xanthine oxidoreductase (XOR) is generally known as the final enzyme in purine metabolism and as a source of reactive oxygen species (ROS). In addition, this enzyme has been suggested to mediate nitric oxide (NO) formation via reduction of inorganic nitrate and nitrite. This NO synthase (NOS)-independent pathway for NO generation is of particular importance during certain conditions when NO bioavailability is diminished due to reduced activity of endothelial NOS (eNOS) or increased oxidative stress, including aging and cardiovascular disease. The exact interplay between NOS- and XOR-derived NO generation is not fully elucidated yet. The aim of the present study was to investigate if eNOS deficiency is associated with changes in XOR expression and activity and the possible impact on nitrite, NO and ROS homeostasis. Plasma levels of nitrate and nitrite were similar between eNOS deficient (eNOS ) and wildtype (wt) mice. XOR activity was upregulated in eNOS compared with wt, but not in nNOS , iNOS or wt mice treated with the non-selective NOS inhibitor L-NAME. Following an acute dose of nitrate, plasma nitrite increased more in eNOS compared with wt, and this augmented response was abolished by the selective XOR inhibitor febuxostat. Livers from eNOS displayed higher nitrite reducing capacity compared with wt, and this effect was attenuated by febuxostat. Dietary supplementation with nitrate increased XOR expression and activity, but concomitantly reduced superoxide generation. The latter effect was also seen in vitro after nitrite administration. Treatment with febuxostat elevated blood pressure in eNOS , but not in wt mice. A high dose of dietary nitrate reduced blood pressure in naïve eNOS mice, and again this effect was abolished by febuxostat. In conclusion, eNOS deficiency is associated with an upregulation of XOR facilitating the nitrate-nitrite-NO pathway and decreasing the generation of ROS. This interplay between XOR and eNOS is proposed to play a significant role in NO homeostasis and blood pressure regulation.</description><subject>Animals</subject><subject>Blood Pressure - drug effects</subject><subject>Endothelial nitric oxide synthase</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Febuxostat</subject><subject>Febuxostat - pharmacology</subject><subject>Gene Expression Regulation</subject><subject>Hypertension</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>NG-Nitroarginine Methyl Ester - pharmacology</subject><subject>Nitrate</subject><subject>Nitrates - blood</subject><subject>Nitrates - pharmacology</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - blood</subject><subject>Nitric Oxide Synthase Type I - antagonists &amp; inhibitors</subject><subject>Nitric Oxide Synthase Type I - deficiency</subject><subject>Nitric Oxide Synthase Type I - genetics</subject><subject>Nitric Oxide Synthase Type II - antagonists &amp; inhibitors</subject><subject>Nitric Oxide Synthase Type II - deficiency</subject><subject>Nitric Oxide Synthase Type II - genetics</subject><subject>Nitric Oxide Synthase Type III - antagonists &amp; inhibitors</subject><subject>Nitric Oxide Synthase Type III - deficiency</subject><subject>Nitric Oxide Synthase Type III - genetics</subject><subject>Nitrite</subject><subject>Nitrites - blood</subject><subject>Nitrites - pharmacology</subject><subject>Oxidation-Reduction</subject><subject>Oxidative stress</subject><subject>Reactive oxygen species</subject><subject>Signal Transduction</subject><subject>Superoxide</subject><subject>Superoxides - metabolism</subject><subject>Uric acid</subject><subject>Xanthine Dehydrogenase - antagonists &amp; inhibitors</subject><subject>Xanthine Dehydrogenase - genetics</subject><subject>Xanthine Dehydrogenase - metabolism</subject><subject>Xanthine oxidase</subject><subject>Xanthine oxidoreductase</subject><issn>1873-4596</issn><issn>0891-5849</issn><issn>1873-4596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1r3DAQxUVoyMe2_0IQ9NJD7erDlu3eQrpJCmEN2bb0JsbSOKvsru1YcsL-91HItuSS03u8-fEYZgj5zFnKGVff7tN2RBzBNq7fok1FDFNWpYxlB-SEl4VMsrxSH974Y3Lq_T2LRC7LI3IsCsUqIfITsp53K-gMWvq3vqVggnt0YUddR3FRLxOLrTMOu0C3zuB3Om9bNMHTvqNhhbRzYYSAyYu6qIuaDhBWT7Cj0Fl6Wy_pKu7Y-wDe-Y_ksIWNx097nZHfl_NfF9fJTX318-L8JhlEqUJSIpPIeVMgNla1mTQSFDSGKws5ByEKZpmxjWmFAWvy0gDEWZZVGVdVI-WMJK-9_gmHqdHD6LYw7nQPTu-jdXSocyZyqSL_9V3-h_tzrvvxTk-TlpwVRRnxL6_4MPYPE_qgt84b3Gygw37ympcylwUXSkT0bI9OTXzV_-Z_95fPC0GN3Q</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Peleli, Maria</creator><creator>Zollbrecht, Christa</creator><creator>Montenegro, Marcelo F</creator><creator>Hezel, Michael</creator><creator>Zhong, Jianghong</creator><creator>Persson, Erik G</creator><creator>Holmdahl, Rikard</creator><creator>Weitzberg, Eddie</creator><creator>Lundberg, Jon O</creator><creator>Carlström, Mattias</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DF2</scope></search><sort><creationdate>20161001</creationdate><title>Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis</title><author>Peleli, Maria ; Zollbrecht, Christa ; Montenegro, Marcelo F ; Hezel, Michael ; Zhong, Jianghong ; Persson, Erik G ; Holmdahl, Rikard ; Weitzberg, Eddie ; Lundberg, Jon O ; Carlström, Mattias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p286t-8e03e11b7eebd6f43c3a6abc16da51a2270d0cdbcf2cadc58caa16d4494169b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Blood Pressure - drug effects</topic><topic>Endothelial nitric oxide synthase</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Febuxostat</topic><topic>Febuxostat - pharmacology</topic><topic>Gene Expression Regulation</topic><topic>Hypertension</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>NG-Nitroarginine Methyl Ester - pharmacology</topic><topic>Nitrate</topic><topic>Nitrates - blood</topic><topic>Nitrates - pharmacology</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - blood</topic><topic>Nitric Oxide Synthase Type I - antagonists &amp; inhibitors</topic><topic>Nitric Oxide Synthase Type I - deficiency</topic><topic>Nitric Oxide Synthase Type I - genetics</topic><topic>Nitric Oxide Synthase Type II - antagonists &amp; inhibitors</topic><topic>Nitric Oxide Synthase Type II - deficiency</topic><topic>Nitric Oxide Synthase Type II - genetics</topic><topic>Nitric Oxide Synthase Type III - antagonists &amp; inhibitors</topic><topic>Nitric Oxide Synthase Type III - deficiency</topic><topic>Nitric Oxide Synthase Type III - genetics</topic><topic>Nitrite</topic><topic>Nitrites - blood</topic><topic>Nitrites - pharmacology</topic><topic>Oxidation-Reduction</topic><topic>Oxidative stress</topic><topic>Reactive oxygen species</topic><topic>Signal Transduction</topic><topic>Superoxide</topic><topic>Superoxides - metabolism</topic><topic>Uric acid</topic><topic>Xanthine Dehydrogenase - antagonists &amp; inhibitors</topic><topic>Xanthine Dehydrogenase - genetics</topic><topic>Xanthine Dehydrogenase - metabolism</topic><topic>Xanthine oxidase</topic><topic>Xanthine oxidoreductase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peleli, Maria</creatorcontrib><creatorcontrib>Zollbrecht, Christa</creatorcontrib><creatorcontrib>Montenegro, Marcelo F</creatorcontrib><creatorcontrib>Hezel, Michael</creatorcontrib><creatorcontrib>Zhong, Jianghong</creatorcontrib><creatorcontrib>Persson, Erik G</creatorcontrib><creatorcontrib>Holmdahl, Rikard</creatorcontrib><creatorcontrib>Weitzberg, Eddie</creatorcontrib><creatorcontrib>Lundberg, Jon O</creatorcontrib><creatorcontrib>Carlström, Mattias</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Uppsala universitet</collection><jtitle>Free radical biology &amp; medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peleli, Maria</au><au>Zollbrecht, Christa</au><au>Montenegro, Marcelo F</au><au>Hezel, Michael</au><au>Zhong, Jianghong</au><au>Persson, Erik G</au><au>Holmdahl, Rikard</au><au>Weitzberg, Eddie</au><au>Lundberg, Jon O</au><au>Carlström, Mattias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis</atitle><jtitle>Free radical biology &amp; medicine</jtitle><addtitle>Free Radic Biol Med</addtitle><date>2016-10-01</date><risdate>2016</risdate><volume>99</volume><spage>472</spage><epage>484</epage><pages>472-484</pages><issn>1873-4596</issn><issn>0891-5849</issn><eissn>1873-4596</eissn><abstract>Xanthine oxidoreductase (XOR) is generally known as the final enzyme in purine metabolism and as a source of reactive oxygen species (ROS). In addition, this enzyme has been suggested to mediate nitric oxide (NO) formation via reduction of inorganic nitrate and nitrite. This NO synthase (NOS)-independent pathway for NO generation is of particular importance during certain conditions when NO bioavailability is diminished due to reduced activity of endothelial NOS (eNOS) or increased oxidative stress, including aging and cardiovascular disease. The exact interplay between NOS- and XOR-derived NO generation is not fully elucidated yet. The aim of the present study was to investigate if eNOS deficiency is associated with changes in XOR expression and activity and the possible impact on nitrite, NO and ROS homeostasis. Plasma levels of nitrate and nitrite were similar between eNOS deficient (eNOS ) and wildtype (wt) mice. XOR activity was upregulated in eNOS compared with wt, but not in nNOS , iNOS or wt mice treated with the non-selective NOS inhibitor L-NAME. Following an acute dose of nitrate, plasma nitrite increased more in eNOS compared with wt, and this augmented response was abolished by the selective XOR inhibitor febuxostat. Livers from eNOS displayed higher nitrite reducing capacity compared with wt, and this effect was attenuated by febuxostat. Dietary supplementation with nitrate increased XOR expression and activity, but concomitantly reduced superoxide generation. The latter effect was also seen in vitro after nitrite administration. Treatment with febuxostat elevated blood pressure in eNOS , but not in wt mice. A high dose of dietary nitrate reduced blood pressure in naïve eNOS mice, and again this effect was abolished by febuxostat. In conclusion, eNOS deficiency is associated with an upregulation of XOR facilitating the nitrate-nitrite-NO pathway and decreasing the generation of ROS. This interplay between XOR and eNOS is proposed to play a significant role in NO homeostasis and blood pressure regulation.</abstract><cop>United States</cop><pmid>27609225</pmid><doi>10.1016/j.freeradbiomed.2016.09.004</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1873-4596
ispartof Free radical biology & medicine, 2016-10, Vol.99, p.472-484
issn 1873-4596
0891-5849
1873-4596
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_502536
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Blood Pressure - drug effects
Endothelial nitric oxide synthase
Enzyme Inhibitors - pharmacology
Febuxostat
Febuxostat - pharmacology
Gene Expression Regulation
Hypertension
Male
Mice
Mice, Knockout
NG-Nitroarginine Methyl Ester - pharmacology
Nitrate
Nitrates - blood
Nitrates - pharmacology
Nitric oxide
Nitric Oxide - blood
Nitric Oxide Synthase Type I - antagonists & inhibitors
Nitric Oxide Synthase Type I - deficiency
Nitric Oxide Synthase Type I - genetics
Nitric Oxide Synthase Type II - antagonists & inhibitors
Nitric Oxide Synthase Type II - deficiency
Nitric Oxide Synthase Type II - genetics
Nitric Oxide Synthase Type III - antagonists & inhibitors
Nitric Oxide Synthase Type III - deficiency
Nitric Oxide Synthase Type III - genetics
Nitrite
Nitrites - blood
Nitrites - pharmacology
Oxidation-Reduction
Oxidative stress
Reactive oxygen species
Signal Transduction
Superoxide
Superoxides - metabolism
Uric acid
Xanthine Dehydrogenase - antagonists & inhibitors
Xanthine Dehydrogenase - genetics
Xanthine Dehydrogenase - metabolism
Xanthine oxidase
Xanthine oxidoreductase
title Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T17%3A47%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhanced%20XOR%20activity%20in%20eNOS-deficient%20mice:%20Effects%20on%20the%20nitrate-nitrite-NO%20pathway%20and%20ROS%20homeostasis&rft.jtitle=Free%20radical%20biology%20&%20medicine&rft.au=Peleli,%20Maria&rft.date=2016-10-01&rft.volume=99&rft.spage=472&rft.epage=484&rft.pages=472-484&rft.issn=1873-4596&rft.eissn=1873-4596&rft_id=info:doi/10.1016/j.freeradbiomed.2016.09.004&rft_dat=%3Cproquest_swepu%3E1835371262%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835371262&rft_id=info:pmid/27609225&rfr_iscdi=true